Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT2306 vs Cosentyx in Healthy Chinese Males
NCT04711343Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAT2306 in plaque psoriasis (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Peak Plasma Concentration and Area Under the Curve (0-inf). Started Jun 2022; status: completed.
02
Drugs
BAT2306
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04711343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711343.